Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy.

In a Comprehensive Meta-analysis comprising 27895 patients, only a trend towards significance was observed in EFS for HR + breast cancer (HR = 0.15; 95 % probability intervals (PI), 0.02–1.10; n = 3385), different from the statistically significant improvement of EFS observed in patients with TNBC (HR = 0.18; 95 % PI, 0.10–0.31; n = 2039) or HER2 positive breast cancer (HR = 0.31; 95 % PI, 0.21–0.50; n = 5711) [ 7 ].

also in 2,760 other papers